Amphastar Pharma receives FDA approval for generic Quelicin

The FDA has approved Amphastar Pharmaceuticals’ (NASDAQ:AMPH) Abbreviated New Drug Application for Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) Multiple-Dose Vial, a therapeutic equivalent of Pfizer’s Quelicin.

It is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

According to IQVIA, the annual U.S sales figure for year March 31, 2020 for Succinylcholine Chloride Injection USP was ~$75M.

https://seekingalpha.com/news/3581420-amphastar-pharma-receives-fda-approval-for-generic-quelicin